U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C6H5NO2
Molecular Weight 123.1094
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of NIACIN

SMILES

OC(=O)C1=CN=CC=C1

InChI

InChIKey=PVNIIMVLHYAWGP-UHFFFAOYSA-N
InChI=1S/C6H5NO2/c8-6(9)5-2-1-3-7-4-5/h1-4H,(H,8,9)

HIDE SMILES / InChI

Molecular Formula C6H5NO2
Molecular Weight 123.1094
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: description was created based on several sources, including http://reference.medscape.com/drug/vitamin-b3-niacor-niacin-344422 https://www.ncbi.nlm.nih.gov/pubmed/16099840

Niacin (also known as vitamin B3 and nicotinic acid) is bio converted to nicotinamide which is further converted to nicotinamide adenine dinucleotide (NAD+) and the hydride equivalent (NADH) which are coenzymes necessary for tissue metabolism, lipid metabolism, and glycogenolysis. Niacin (but not nicotinamide) in gram doses reduces LDL-C, Apo B, Lp(a), TG, and TC, and increases HDL-C. The increase in HDL-C is associated with an increase in apolipoprotein A-I (Apo A-I) and a shift in the distribution of HDL subfractions. These shifts include an increase in the HDL2:HDL3 ratio, and an elevation in lipoprotein A-I (Lp A-I, an HDL-C particle containing only Apo A-I). The mechanism by which niacin alters lipid profiles is not completely understood and may involve several actions, including partial inhibition of release of free fatty acids from adipose tissue, and increased lipoprotein lipase activity (which may increase the rate of chylomicron triglyceride removal from plasma). Niacin decreases the rate of hepatic synthesis of VLDL-C and LDL-C, and does not appear to affect fecal excretion of fats, sterols, or bile acids. As an adjunct to diet, the efficacy of niacin and lovastatin in improving lipid profiles (either individually, or in combination with each other, or niacin in combination with other statins) for the treatment of dyslipidemia has been well documented. The effect of combined therapy with niacin and lovastatin on cardiovascular morbidity and mortality has not been determined. In addition, preliminary reports suggest that niacin causes favorable LDL particle size transformations, although the clinical relevance of this effect is not yet clear. April 15, 2016: Based on several large cardiovascular outcome trials including AIM-HIGH, ACCORD, and HPS2-THRIVE, the FDA decided that "scientific evidence no longer supports the conclusion that a drug-induced reduction in triglyceride levels and/or increase in HDL-cholesterol levels in statin-treated patients results in a reduction in the risk of cardiovascular events" Consistent with this conclusion, the FDA has determined that the benefits of niacin ER tablets for coadministration with statins no longer outweigh the risks, and the approval for this indication should be withdrawn.

CNS Activity

Curator's Comment: Niacin penetration into CSF and the extracellular space of brain from plasma as well as regulation of entry into brain cells by a saturable accumulation system are two distinct parts of the homeostatic system. In vivo, niacin that enters the central nervous system is converted to the principal plasma vitamer, niacinamide, in its free or bound forms such as NAD.

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Preventing
NIASPAN

Approved Use

To reduce the risk of recurrent nonfatal myocardial infarction in patients with a history of myocardial infarction and hyperlipidemia.

Launch Date

1997
Palliative
NIASPAN

Approved Use

In combination with a bile acid binding resin slows progression or promotes regression of atherosclerotic disease in patients with a history of coronary artery disease (CAD) and hyperlipidemia.

Launch Date

1997
Primary
NIASPAN

Approved Use

NIASPAN contains extended-release niacin (nicotinic acid), and is indicated to reduce elevated TC, LDL-C, Apo B and TG, and to increase HDL-C in patients with primary hyperlipidemia and mixed dyslipidemia.

Launch Date

1997
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
5.39 μg/mL
2000 mg single, oral
dose: 2000 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
NIACIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
1150 μg × min/mL
2000 mg single, oral
dose: 2000 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
NIACIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
30 min
2000 mg single, oral
dose: 2000 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
NIACIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG



Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
yes [Ki 114 uM]
yes [Ki 19 uM]
yes [Ki 237 uM]
yes [Ki 44 uM]
yes [Ki 541 uM]
Drug as victim
Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
The solvent shells of cluster ions produced by direct electric field extraction from glycerol/water mixtures.
2001
Do breastfed infants need supplemental vitamins?
2001 Apr
Utility of PCR assays for rapid diagnosis of BCG infection in children.
2001 Apr
Dietary inadequacies observed in homeless men visiting an emergency night shelter in Paris.
2001 Apr
Carbohydrate metabolism during exercise in females: effect of reduced fat availability.
2001 Apr
Treatment of hyperlipidemia in HIV-infected patients.
2001 Apr 1
A new niacin. Vitamin with an HDL kick.
2001 Apr 16
DNA damage from micronutrient deficiencies is likely to be a major cause of cancer.
2001 Apr 18
Pharmacology of H 394/84, a dihydropyridine neuropeptide Y Y(1) receptor antagonist, in vivo.
2001 Apr 20
Ion interaction reagent reversed-phase high-performance liquid chromatography determination of anti-tuberculosis drugs and metabolites in biological fluids.
2001 Apr 25
Angiotensin II type I receptor modulates intracellular free Mg2+ in renally derived cells via Na+-dependent Ca2+-independent mechanisms.
2001 Apr 27
Lack of association between schizophrenia and the phospholipase-A(2) genes cPLA2 and sPLA2.
2001 Apr 8
The relationship among dental status, nutrient intake, and nutritional status in older people.
2001 Feb
Perchlorate stimulates insulin secretion by shifting the gating of L-type Ca2+ currents in mouse pancreatic B-cells towards negative potentials.
2001 Feb
Abnormality of calcium channel inhibitor released from fetal membranes in preterm labor.
2001 Feb
Etofibrate but not controlled-release niacin decreases LDL cholesterol and lipoprotein (a) in type IIb dyslipidemic subjects.
2001 Feb
Characterization of a G protein-coupled receptor for nicotinic acid.
2001 Feb
Biophysical properties, pharmacology, and modulation of human, neuronal L-type (alpha(1D), Ca(V)1.3) voltage-dependent calcium currents.
2001 Feb
Down-regulation of L-type calcium channels in inflamed circular smooth muscle cells of the canine colon.
2001 Feb
Common hepatic lipase gene promoter variant determines clinical response to intensive lipid-lowering treatment.
2001 Feb 13
Safety and effectiveness of Niaspan when added sequentially to a statin for treatment of dyslipidemia.
2001 Feb 15
Chronic nicotine alters NO signaling of Ca(2+) channels in cerebral arterioles.
2001 Feb 16
Differential effects of agonists of aldosterone secretion on steroidogenic acute regulatory phosphorylation.
2001 Feb 28
Cellular mechanisms of depressed atrial contractility in patients with chronic atrial fibrillation.
2001 Feb 6
Effects of nicotinamide coenzymes on the stability of enzyme activities and proteins in niacin-deficient quail tissues against trypsin treatment.
2001 Jan
Lp(a) lipoprotein--an independent risk factor for coronary heart disease after menopause.
2001 Jan
The nicotinamide biosynthetic pathway is a by-product of the RNA world.
2001 Jan
Effects of PKC isozyme inhibitors on constrictor responses in the feline pulmonary vascular bed.
2001 Jan
[The role of HDL in the prevention of cardiovascular events].
2001 Jan 21
Downregulation of the voltage-dependent calcium channel (VDCC) beta-subunit mRNAs in pancreatic islets of type 2 diabetic rats.
2001 Jan 26
Complex intracellular messenger pathways regulate one type of neuronal alpha-bungarotoxin-resistant nicotinic acetylcholine receptors expressed in insect neurosecretory cells (dorsal unpaired median neurons).
2001 Jul
Hypoxia-induced upregulation of eNOS gene expression is redox-sensitive: a comparison between hypoxia and inhibitors of cell metabolism.
2001 Jul
[Drug combination therapies for patients with hyperlipidemia and its significance].
2001 Mar
Lipids and atherosclerosis: clinical management of hypercholesterolaemia.
2001 Mar
Mechanism of CGRP-induced relaxation in rat intramural coronary arteries.
2001 Mar
Pellagra in 2 homeless men.
2001 Mar
Signalling mechanisms underlying the myogenic response in human subcutaneous resistance arteries.
2001 Mar
Regulation of Ca2+-sensitive adenylyl cyclase in gonadotropin-releasing hormone neurons.
2001 Mar
Activation of purified cardiac ryanodine receptors by dihydropyridine agonists.
2001 Mar
Effect of nicotinic acid administration on hepatic very low density lipoprotein-triglyceride production.
2001 Mar
Reduction of lipoprotein(a) in postmenopausal women.
2001 Mar 12
Effect of beta-estradiol on voltage-gated Ca(2+) channels in rat hippocampal neurons: a comparison with dehydroepiandrosterone.
2001 Mar 30
Calcium buffering of resting, voltage-dependent Ca2+ influx by sarcoplasmic reticulum in femoral arteries from spontaneously hypertensive rats at prehypertensive stage.
2001 May
Determination by capillary electrophoresis of total and available niacin in different development stage of raw and processed legumes: comparison with high-performance liquid chromatography.
2001 May
The application of capillary electrophoresis to the analysis of vitamins in food and beverages.
2001 May
Determination of additives in food by capillary electrophoresis.
2001 May
New recommendations from the 1999 American College of Cardiology/American Heart Association acute myocardial infarction guidelines.
2001 May
Sites and ionic mechanisms of hypoxic vasoconstriction in frog skin.
2001 May
Effects of dextromethorphan on the seizures induced by kainate and the calcium channel agonist BAY k-8644: comparison with the effects of dextrorphan.
2001 May
Niacin in patients with diabetes mellitus and coronary artery disease.
2001 May 1
Patents

Sample Use Guides

Patients not currently on NIASPAN must start ADVICOR at the lowest initial ADVICOR dose, a single 500 mg/20 mg tablet once daily at bedtime. The dose of ADVICOR should not be increased by more than 500 mg daily (based on the NIASPAN component) every 4 weeks. The dose of ADVICOR should be individualized based on targeted goals for cholesterol and triglycerides, and on patient response. Doses of ADVICOR greater than 2000 mg/40 mg daily are not recommended.
Route of Administration: Oral
HepG2 cells were preincubated for 48 hours with varying concentrations of niacin (0 to 3.0 mmol/L) in DMEM containing 10% FBS media. Incubation of HepG2 cells with niacin significantly inhibited (by 12% to 15%) fatty acid esterification to produce TG as assessed by the incorporation of 3H-oleic acid into TG. 14C-acetate incorporation into cholesterol and phospholipids was unchanged. The activity of microsomal triglyceride transfer protein MTP), a carrier protein for lipids, was not altered by pretreatment of cells with niacin.
Substance Class Chemical
Created
by admin
on Fri Dec 15 16:35:47 GMT 2023
Edited
by admin
on Fri Dec 15 16:35:47 GMT 2023
Record UNII
2679MF687A
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
NIACIN
FCC   HSDB   INCI   ORANGE BOOK   USP   USP-RS   VANDF  
INCI  
Official Name English
ADVICOR COMPONENT NIACIN
Common Name English
WAMPOCAP
Brand Name English
VITAMIN B3 [VANDF]
Common Name English
3-PYRIDINECARBOXYLIC ACID
Systematic Name English
NICOTINIC ACID [MI]
Common Name English
Nicotinic acid
EMA EPAR   EP   INN   MART.   MI   VANDF   WHO-DD   WHO-IP  
INN  
Official Name English
SIMCOR COMPONENT NIACIN
Common Name English
NIACIN [USP MONOGRAPH]
Common Name English
METHYL NICOTINATE IMPURITY A [EP IMPURITY]
Common Name English
NICOTINIC ACID [EMA EPAR]
Common Name English
NSC-169454
Code English
nicotinic acid [INN]
Common Name English
NICOTINIC ACID [EP MONOGRAPH]
Common Name English
NICOTINIC ACID [MART.]
Common Name English
NIACIN COMPONENT OF ADVICOR
Common Name English
NIACIN [INCI]
Common Name English
NIACIN [ORANGE BOOK]
Common Name English
NICOLAR
Brand Name English
ACIDUM NICOTINICUM [WHO-IP LATIN]
Common Name English
NICOTINIC ACID [WHO-IP]
Common Name English
NIACIN [HSDB]
Common Name English
NIACIN [FCC]
Common Name English
NICOTINIC ACID [JAN]
Common Name English
NIACIN [VANDF]
Common Name English
NIACIN [USP-RS]
Common Name English
Nicotinic acid [WHO-DD]
Common Name English
VITAMIN B3
VANDF  
Common Name English
NIASPAN
Brand Name English
NICOTINIC ACID [EP IMPURITY]
Common Name English
NIACIN COMPONENT OF SIMCOR
Common Name English
NICOTINIC ACID [VANDF]
Common Name English
NIACOR
Brand Name English
NIACIN EXTENDED RELEASE
Common Name English
VITAMIN B-3
Systematic Name English
Classification Tree Code System Code
WHO-VATC QC10AD52
Created by admin on Fri Dec 15 16:35:47 GMT 2023 , Edited by admin on Fri Dec 15 16:35:47 GMT 2023
LIVERTOX NBK548176
Created by admin on Fri Dec 15 16:35:47 GMT 2023 , Edited by admin on Fri Dec 15 16:35:47 GMT 2023
LIVERTOX NBK548710
Created by admin on Fri Dec 15 16:35:47 GMT 2023 , Edited by admin on Fri Dec 15 16:35:47 GMT 2023
NDF-RT N0000175594
Created by admin on Fri Dec 15 16:35:47 GMT 2023 , Edited by admin on Fri Dec 15 16:35:47 GMT 2023
WHO-VATC QC04AC01
Created by admin on Fri Dec 15 16:35:47 GMT 2023 , Edited by admin on Fri Dec 15 16:35:47 GMT 2023
CFR 21 CFR 184.1530
Created by admin on Fri Dec 15 16:35:47 GMT 2023 , Edited by admin on Fri Dec 15 16:35:47 GMT 2023
LOINC 10836-5
Created by admin on Fri Dec 15 16:35:47 GMT 2023 , Edited by admin on Fri Dec 15 16:35:47 GMT 2023
EPA PESTICIDE CODE 56701
Created by admin on Fri Dec 15 16:35:47 GMT 2023 , Edited by admin on Fri Dec 15 16:35:47 GMT 2023
WHO-VATC QC10AD02
Created by admin on Fri Dec 15 16:35:47 GMT 2023 , Edited by admin on Fri Dec 15 16:35:47 GMT 2023
DSLD 2544 (Number of products:3520)
Created by admin on Fri Dec 15 16:35:47 GMT 2023 , Edited by admin on Fri Dec 15 16:35:47 GMT 2023
NDF-RT N0000007641
Created by admin on Fri Dec 15 16:35:47 GMT 2023 , Edited by admin on Fri Dec 15 16:35:47 GMT 2023
WHO-ATC C10AD52
Created by admin on Fri Dec 15 16:35:47 GMT 2023 , Edited by admin on Fri Dec 15 16:35:47 GMT 2023
LOINC 34342-6
Created by admin on Fri Dec 15 16:35:47 GMT 2023 , Edited by admin on Fri Dec 15 16:35:47 GMT 2023
WHO-VATC QC10BA01
Created by admin on Fri Dec 15 16:35:47 GMT 2023 , Edited by admin on Fri Dec 15 16:35:47 GMT 2023
DSLD 1570 (Number of products:100)
Created by admin on Fri Dec 15 16:35:47 GMT 2023 , Edited by admin on Fri Dec 15 16:35:47 GMT 2023
NCI_THESAURUS C45812
Created by admin on Fri Dec 15 16:35:47 GMT 2023 , Edited by admin on Fri Dec 15 16:35:47 GMT 2023
WHO-ATC C10BA01
Created by admin on Fri Dec 15 16:35:47 GMT 2023 , Edited by admin on Fri Dec 15 16:35:47 GMT 2023
CFR 21 CFR 102.23
Created by admin on Fri Dec 15 16:35:47 GMT 2023 , Edited by admin on Fri Dec 15 16:35:47 GMT 2023
NDF-RT N0000007641
Created by admin on Fri Dec 15 16:35:47 GMT 2023 , Edited by admin on Fri Dec 15 16:35:47 GMT 2023
LOINC 18244-4
Created by admin on Fri Dec 15 16:35:47 GMT 2023 , Edited by admin on Fri Dec 15 16:35:47 GMT 2023
LOINC 2656-7
Created by admin on Fri Dec 15 16:35:47 GMT 2023 , Edited by admin on Fri Dec 15 16:35:47 GMT 2023
WHO-ATC C04AC01
Created by admin on Fri Dec 15 16:35:47 GMT 2023 , Edited by admin on Fri Dec 15 16:35:47 GMT 2023
DSLD 204 (Number of products:661)
Created by admin on Fri Dec 15 16:35:47 GMT 2023 , Edited by admin on Fri Dec 15 16:35:47 GMT 2023
WHO-ATC C10AD02
Created by admin on Fri Dec 15 16:35:47 GMT 2023 , Edited by admin on Fri Dec 15 16:35:47 GMT 2023
LOINC 79402-4
Created by admin on Fri Dec 15 16:35:47 GMT 2023 , Edited by admin on Fri Dec 15 16:35:47 GMT 2023
Code System Code Type Description
DRUG CENTRAL
2835
Created by admin on Fri Dec 15 16:35:47 GMT 2023 , Edited by admin on Fri Dec 15 16:35:47 GMT 2023
PRIMARY
NCI_THESAURUS
C689
Created by admin on Fri Dec 15 16:35:47 GMT 2023 , Edited by admin on Fri Dec 15 16:35:47 GMT 2023
PRIMARY
MESH
D009525
Created by admin on Fri Dec 15 16:35:47 GMT 2023 , Edited by admin on Fri Dec 15 16:35:47 GMT 2023
PRIMARY
ChEMBL
CHEMBL573
Created by admin on Fri Dec 15 16:35:47 GMT 2023 , Edited by admin on Fri Dec 15 16:35:47 GMT 2023
PRIMARY
EVMPD
SUB09247MIG
Created by admin on Fri Dec 15 16:35:47 GMT 2023 , Edited by admin on Fri Dec 15 16:35:47 GMT 2023
PRIMARY
MERCK INDEX
m7880
Created by admin on Fri Dec 15 16:35:47 GMT 2023 , Edited by admin on Fri Dec 15 16:35:47 GMT 2023
PRIMARY Merck Index
WIKIPEDIA
NIACIN
Created by admin on Fri Dec 15 16:35:47 GMT 2023 , Edited by admin on Fri Dec 15 16:35:47 GMT 2023
PRIMARY
CHEBI
176839
Created by admin on Fri Dec 15 16:35:47 GMT 2023 , Edited by admin on Fri Dec 15 16:35:47 GMT 2023
PRIMARY
PUBCHEM
938
Created by admin on Fri Dec 15 16:35:47 GMT 2023 , Edited by admin on Fri Dec 15 16:35:47 GMT 2023
PRIMARY
FDA UNII
2679MF687A
Created by admin on Fri Dec 15 16:35:47 GMT 2023 , Edited by admin on Fri Dec 15 16:35:47 GMT 2023
PRIMARY
CHEBI
17154
Created by admin on Fri Dec 15 16:35:47 GMT 2023 , Edited by admin on Fri Dec 15 16:35:47 GMT 2023
PRIMARY
EPA CompTox
DTXSID1020932
Created by admin on Fri Dec 15 16:35:47 GMT 2023 , Edited by admin on Fri Dec 15 16:35:47 GMT 2023
PRIMARY
CHEBI
15940
Created by admin on Fri Dec 15 16:35:47 GMT 2023 , Edited by admin on Fri Dec 15 16:35:47 GMT 2023
PRIMARY
RS_ITEM_NUM
1461003
Created by admin on Fri Dec 15 16:35:47 GMT 2023 , Edited by admin on Fri Dec 15 16:35:47 GMT 2023
PRIMARY
SMS_ID
100000092214
Created by admin on Fri Dec 15 16:35:47 GMT 2023 , Edited by admin on Fri Dec 15 16:35:47 GMT 2023
PRIMARY
ECHA (EC/EINECS)
200-441-0
Created by admin on Fri Dec 15 16:35:47 GMT 2023 , Edited by admin on Fri Dec 15 16:35:47 GMT 2023
PRIMARY
NSC
169454
Created by admin on Fri Dec 15 16:35:47 GMT 2023 , Edited by admin on Fri Dec 15 16:35:47 GMT 2023
PRIMARY
INN
373
Created by admin on Fri Dec 15 16:35:47 GMT 2023 , Edited by admin on Fri Dec 15 16:35:47 GMT 2023
PRIMARY
HSDB
3134
Created by admin on Fri Dec 15 16:35:47 GMT 2023 , Edited by admin on Fri Dec 15 16:35:47 GMT 2023
PRIMARY
DRUG BANK
DB00627
Created by admin on Fri Dec 15 16:35:47 GMT 2023 , Edited by admin on Fri Dec 15 16:35:47 GMT 2023
PRIMARY
RXCUI
7393
Created by admin on Fri Dec 15 16:35:47 GMT 2023 , Edited by admin on Fri Dec 15 16:35:47 GMT 2023
PRIMARY RxNorm
WHO INTERNATIONAL PHARMACOPEIA
NIACIN
Created by admin on Fri Dec 15 16:35:47 GMT 2023 , Edited by admin on Fri Dec 15 16:35:47 GMT 2023
PRIMARY Description: Colourless crystals or a white, crystalline powder; odourless or almost odourless. Solubility: Sparingly soluble in water; freely soluble in boiling water; soluble in 100 parts of ethanol (~750 g/l) TS; practicallyinsoluble in ether R. Category: Component of vitamin B complex; vasodilator. Storage: Nicotinic acid should be kept in a well-closed container, protected from light. Definition: Nicotinic acid contains not less than 99.0% and not more than 101.0% of C6H5NO2, calculated with reference to thedried substance.
CAS
59-67-6
Created by admin on Fri Dec 15 16:35:47 GMT 2023 , Edited by admin on Fri Dec 15 16:35:47 GMT 2023
PRIMARY
DAILYMED
2679MF687A
Created by admin on Fri Dec 15 16:35:47 GMT 2023 , Edited by admin on Fri Dec 15 16:35:47 GMT 2023
PRIMARY
Related Record Type Details
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
PARENT -> CONSTITUENT ALWAYS PRESENT
Nutritional value per 100 g (3.5 oz) - 0.639 mg (4%)
SALT/SOLVATE -> PARENT
TARGET -> AGONIST
AGONIST
EC50
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
Related Record Type Details
METABOLITE -> PARENT
METABOLITE -> PARENT
Related Record Type Details
PARENT -> IMPURITY
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Biological Half-life PHARMACOKINETIC Elimination
PHARMACOKINETIC